ROR1 ADC: AxcynDOTTM Dual Payload Platform

By | 28 January 2026

Outlining a dual-payload ADC platform for next-generation therapeutics
Discovering anti-ROR1 ADC candidates
Sharing a preclinical evaluation supporting enhanced anti-tumor activity and overcoming resistance